Japan Cancer Gene Therapy Market Size, Share, and COVID-19 Impact Analysis, By Therapy (Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer), By End User (Hospitals, Diagnostic Centers, and Research Institutes), and Japan Cancer Gene Therapy Market Insights, Industry Trend, Forecasts to 2033

Japan Cancer Gene Therapy Market Insights Forecasts to 2033

• The Japan Cancer Gene Therapy Market Size is Growing at a CAGR of 23.35% from 2023 to 2033
• The Japan Cancer Gene Therapy Market Size is Expected to Reach a Significant Share by 2033

The Japan Cancer Gene Therapy Market Size is anticipated to reach a significant share by 2033, Growing at a CAGR of 23.35% from 2023 to 2033.

Market Overview

Japan cancer gene therapy market refers to the application of gene therapy techniques aimed at treating cancer by altering the genetic material within a patient's cells to fight or prevent the disease. Gene therapy involves introducing, removing, or modifying genetic material in a patient's cells to correct defective genes or enhance the body's natural ability to fight cancer. Japan, known for its robust healthcare infrastructure, advanced research capabilities, and strong pharmaceutical industry, is at the forefront of adopting and developing gene therapies for cancer treatment. Gene therapy offers numerous benefits, including the potential for targeted treatments that address the root causes of cancer, minimizing side effects compared to traditional therapies like chemotherapy and radiation. The Japanese market is witnessing a surge in research and clinical trials focusing on innovative treatments such as viral vector-based therapies, CRISPR-Cas9 gene editing, and immunogene therapies. With Japan's aging population and a high incidence of cancer, there is a growing emphasis on developing cutting-edge solutions to improve cancer treatment outcomes. Regulatory support from the Japanese government and collaboration between biotech companies, academic institutions, and healthcare providers are further contributing to the growth of the cancer gene therapy market in Japan.

Report Coverage

This research report categorizes the market for the Japan cancer gene therapy market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan cancer gene therapy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan cancer gene therapy market.

Driving Factors

Japanese government's supportive policies, including funding for medical research and regulatory approval for gene therapies, contribute significantly to market expansion. The increasing number of clinical trials, along with advancements in gene-editing technologies like CRISPR, have also accelerated the development of novel cancer therapies.

Restraining Factors

Concerns about the long-term safety and potential side effects of gene therapies, as well as the limited clinical data available for certain therapies, may cause hesitation among both healthcare providers and patients.

Market Segmentation

The Japan cancer gene therapy market share is classified into therapy and end user.

• The gene induced immunotherapy segment accounted for the leading revenue share in 2023 and is expected to grow at a significant CAGR during the forecast period.

The Japan cancer gene therapy market is segmented by therapy into gene induced immunotherapy, oncolytic virotherapy, and gene transfer. Among these, the gene induced immunotherapy segment accounted for the leading revenue share in 2023 and is expected to grow at a significant CAGR during the forecast period. The segment growth is driven because gene-induced immunotherapy focuses on enhancing the body's immune system to target and eliminate cancer cells, offering a promising treatment approach for various cancers. Its rapid growth can be attributed to the increasing number of clinical trials demonstrating its potential effectiveness, as well as the rising demand for targeted and personalized cancer treatments.

• The hospitals segment accounted for the largest market share in 2023 and is expected to grow at a remarkable CAGR during the forecast period.

The Japan cancer gene therapy market is segmented by end user into hospitals, diagnostic centers, and research institutes. Among these, the hospitals segment accounted for the largest market share in 2023 and is expected to grow at a remarkable CAGR during the forecast period. The segment growth can be attributed to the increasing adoption of advanced cancer therapies within hospital settings, where patients can access comprehensive treatment options, including gene therapies.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan cancer gene therapy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Kayropharma Therapeutics
• Glaxosmithkline PLC
• Novartis
• Amgen Inc.
• Genulex Corporation
• shanghai sunway biotech
• Bristol Myers Squibb Co.
• SynerGene Therapeutics
• Adapta Immue
• Gilead Sciences
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In September 2024, Otsuka Pharmaceutical, in collaboration with the National Cancer Center Japan and other institutions, received approval for HemeSight®, a comprehensive genomic profiling assay for hematological malignancies. This test enables personalized treatment strategies based on genetic abnormalities.

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Japan cancer gene therapy market based on the below-mentioned segments:

Japan Cancer Gene Therapy Market, By Therapy

• Gene Induced Immunotherapy
• Oncolytic Virotherapy
• Gene Transfer

Japan Cancer Gene Therapy Market, By End User

• Hospitals
• Diagnostic Centers
• Research Institutes